Choose Your Country or Region

NMDA (N-Methyl-D-aspartic acid)

Name: NMDA (N-Methyl-D-aspartic acid)
Brand: Selleck Chemicals
SKU: S7072
Rating: 5 (7 reviews)

Catalog No.S7072 Purity: 100%

NMDA（N-Methyl-D-aspartic acid）is a specific agonist for NMDA receptor mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor. Phase 4.

NMDA (N-Methyl-D-aspartic acid) Chemical Structure

CAS: 6384-92-5

Selleck's NMDA (N-Methyl-D-aspartic acid) has been cited by 7 publications

Purity & Quality Control

Batch: Purity: 100.00%

100

NMDA (N-Methyl-D-aspartic acid) Related Products

Related Targets	NMDA receptor	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Choose Selective NMDAR Inhibitors

Biological Activity

Description

NMDA（N-Methyl-D-aspartic acid）is a specific agonist for NMDA receptor mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor. Phase 4.

Targets

NMDA receptor ^[1]

In vitro
In vitro	NMDA is an excitatory amino acid neurotransmitter, which only binds to the NMDA receptor without effecting other glutamate receptors (such as those for AMPA and kainate). NMDA specifically binds to the NR2 subunits of NMDA receptor, and then stimulates the open of non-specific cation channel which can allow the passage of Ca²⁺ and Na⁺ into the cell and K⁺ out of the cell. Activation of the NMDA receptor is able to produce the excitatory postsynaptic potential (EPSP), and trigger the increase of intracellular Ca²⁺ content which may further take participating in various signaling pathways. NMDA receptor plays a key role in a wide range of physiological (e.g. long-term potentiation and neuronal plasticity) and pathological processes (e.g. excitotoxicity and epilepsy). ^[1]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT06185790	Recruiting	Mitochondrial Diseases\|Diabetes-Deafness Syndrome Maternally Transmitted	Radboud University Medical Center\|Stichting Stofwisselkracht	January 1 2024	Not Applicable
NCT05954468	Recruiting	NMDAR Antibody-associated Auto-immune Encephalitis	Hospices Civils de Lyon	October 9 2023	--
NCT06183788	Recruiting	Anti-NMDA Receptor Encephalitis	Fundacion Clinic per a la Recerca Biomédica\|Hospital Sant Joan de Deu	January 16 2023	Not Applicable
NCT05650229	Active not recruiting	Primary Mitochondrial Disease	Abliva AB	December 13 2022	Phase 2
NCT05503264	Recruiting	NMDAR Autoimmune Encephalitis\|LGI1 Autoimmune Encephalitis	Hoffmann-La Roche\|Chugai Pharmaceutical Co.	September 27 2022	Phase 3

References

[1] Cull-Candy S, et al. Curr Opin Neurobiol, 2001, 11(3), 327-335.

Chemical Information & Solubility

Molecular Weight	147.13	Formula	C₅H₉NO₄
CAS No.	6384-92-5	SDF	Download NMDA (N-Methyl-D-aspartic acid) SDF
Smiles	CNC(CC(=O)O)C(=O)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

Water : 29 mg/mL

DMSO : 15 mg/mL ( (101.95 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):